pyrroles has been researched along with fluorobenzenes in 331 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.30) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 138 (41.69) | 29.6817 |
| 2010's | 188 (56.80) | 24.3611 |
| 2020's | 4 (1.21) | 2.80 |
| Authors | Studies |
|---|---|
| Crippen, GM; Ghose, AK | 1 |
| Stein, EA | 3 |
| McKellar, J; Mizan, J; Olsson, AG; Pears, J; Raza, A | 1 |
| Chitra, R; Davidson, M; Gotto, AM; Hutchinson, H; Ma, P; Raza, A; Stein, EA | 1 |
| Lin, JH; Mu, L; Prueksaritanont, T; Qiu, Y; Subramanian, R; Tang, C | 1 |
| Istad, H; Luurila, O; Olsson, AG; Ose, L; Pears, J; Southworth, H; Stender, S; Tuomilehto, J; Wiklund, O; Wilpshaar, JW | 1 |
| Ballantyne, CM; Chitra, RR; Knopp, RH; McPherson, R; Schneck, DW; Simonson, SG | 1 |
| Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA | 1 |
| Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J | 2 |
| Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ | 1 |
| Berry, DA; Berry, SM; McKellar, J; Pearson, TA | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Davidson, MH; Jones, PH; McKenney, JM; Miller, E; Stein, EA | 1 |
| Diggle, PJ; Miller, E; Southworth, H; Stein, EA; Strutt, K | 1 |
| Adamczyk, MA; Blasetto, JW; Bryzinski, BS; Cain, VA; Jones, PH; McKenney, JM | 1 |
| Blasetto, J; Caplan, R; Dane, A; Hutchison, H; Strutt, K | 1 |
| Edwards, JE; Moore, RA | 1 |
| Burk, MJ; Chen, P; Greenberg, WA; Hanson, SR; Huang, H; Varvak, A; Wong, K | 1 |
| Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Mason, P | 1 |
| Desai, A; Gawde, A; Jain, MM; Jayaram, S; Naikawadi, AA | 1 |
| Bolognese, MA; Caplan, R; Cressman, M; Hutchinson, H; Raza, A; Schwartz, GG; Tremblay, BP | 1 |
| Basile, AS; Lippa, AS; Skolnick, P | 1 |
| Blasetto, JW; Caplan, RJ; Ferdinand, KC; Gold, A; Hunninghake, DB; Jones, PH; Stein, EA | 1 |
| Dolan, JG; Nautiyal, A; Singh, S | 1 |
| Busso, N; Chobaz, V; Gabay, C; Palmer, G; So, A; Talabot-Ayer, D; Taylor, S | 1 |
| Feely, J; Sigurdsson, EL; Strandberg, TE | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Hirsch, M; Jones, P; O'Donnell, JC | 1 |
| Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C | 1 |
| Jones, P; Miller, PS; Smith, DG | 1 |
| Franken, AA; Vincent, HH; Wolffenbuttel, BH | 1 |
| Barter, P; Kallend, D; Schuster, H; Stender, S; Watkins, C | 1 |
| Cardona-Muñoz, EG; Fonseca, FA; Fuenmayor, N; Marotti, M; Ruiz, A; Silva, JM | 1 |
| McKenney, JM | 1 |
| Boehlen, F; Daali, Y; de Moerloose, P; Fontana, P; Mach, F; Reber, G; Senouf, D; Sigwart, U | 1 |
| Carbonell, T; Freire, E | 1 |
| Ballantyne, CM; Murin, J; Rose, H; Sarti, C; Stalenhoef, AF; Tonstad, S; Wilpshaar, W | 1 |
| Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Shashikumar, D; Srinivas, NR | 1 |
| Hirsch, M; O'donnell, J; Olsson, A | 1 |
| Juszczyk, MA; Seip, RL; Thompson, PD | 1 |
| Davidson, M | 1 |
| Berne, C; Jørgensen, L; Sager, P; Siewert-Delle, A; Sorof, J | 1 |
| Dunselman, PH; Jukema, JW; Liem, AH; Lok, DJ; van der Sloot, JA; Zwinderman, AH | 1 |
| Bots, AF; Kastelein, JJ | 1 |
| Fujino, H; Iwaki, K; Jin, JS; Kakumoto, M; Komoto, C; Nakamura, T; Nishiguchi, K; Okamura, N; Okumura, K; Sakaeda, T | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Barnes, BO; Brown, CD; Clark, LT; Cox, WR; Ferdinand, KC; Gold, A; Isaacsohn, J; Kong, BW; Neal, RC; Sager, PT; Watson, KE; Ycas, J; Zieve, FJ | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Ballantyne, CM; Bertolami, M; Cain, VA; Hernandez Garcia, HR; Nul, D; Raichlen, JS; Stein, EA; Theroux, P; Weiss, R | 1 |
| Berneis, K; Rizzo, M | 1 |
| Elisaf, MS; Filippatos, TD; Ganotakis, ES; Gazi, IF; Goudevenos, J; Kostapanos, M; Mikhailidis, DP; Milionis, HJ; Rizos, E | 1 |
| Binbrek, AS; Fonseca, FA; Middleton, A; Strandberg, TE; Watkins, C; Wilpshaar, W | 1 |
| Einecke, D | 2 |
| Knopp, RH; Paramsothy, P | 1 |
| Haffner, S; Lloret, R; Stein, M; Ycas, J | 1 |
| Guthrie, RM | 1 |
| Fox, KM; Gandhi, SK; McKenney, JM; Ohsfeldt, RL; Stacy, TA | 1 |
| Leiter, LA; Miller, P; Palmer, M; Reckless, JP; Rosenson, RS; Schleman, M; Schulte, KL; Sosef, F; Stein, E | 1 |
| Bays, HE; Jones, PH; Kashyap, ML; Knopp, RH; McGovern, ME; McKenney, JM; Ruoff, GE | 1 |
| Borok, GM; Bullano, MF; Gandhi, SK; Kamat, S; McDonough, KL; Wertz, DA; Willey, VJ | 1 |
| Galgóczy, L; Leiter, E; Lukács, G; Papp, T; Pócsi, I; Vágvölgyi, C | 1 |
| Asztalos, BF; Dallal, GE; Horvath, KV; Jones, PH; Le Maulf, F; McTaggart, F; Schaefer, EJ; Stein, E | 1 |
| Betteridge, DJ; Gibson, JM | 1 |
| Fredrikson, H; Neuvonen, PJ; Niemi, M; Pasanen, MK | 1 |
| Chadarevian, R; Danchin, N; Gayet, JL; Licour, M; Valensi, P | 1 |
| Lavie, CJ; Milani, RV; O'Keefe, JH | 1 |
| Gandhi, SK; Ghali, JK; Hassman, DR; Insull, W; Miller, E; Y As, JW | 1 |
| Deedwania, PC; Gold, A; Gupta, M; Stein, M; Ycas, J | 1 |
| Frial, T; Miller, PS; Tran, YB | 1 |
| Bennett, MT; Bondy, GP; Johns, KW | 1 |
| Askew, V; Auerbach, B; Bainbridge, G; Bratton, LD; Caspers, N; Chen, H; Cheng, XM; Choi, C; Dillon, L; Eberstadt, M; Erasga, N; Hanselman, JC; Harris, MS; Larsen, SD; Lee, C; Lin, Z; Lu, G; Mertz, T; Miller, SR; Olsen, K; Pavlovsky, A; Pfefferkorn, JA; Poel, TJ; Robertson, A; Sekerke, C; Song, Y; Sorenson, RJ; Sun, KL; Trivedi, BK; Unangst, PC | 1 |
| Gao, RL | 1 |
| Gruber, HJ; Landl, EM; März, W; Mayer, C; Pailer, S; Scharnagl, H; Truschnig-Wilders, M | 1 |
| Bergheanu, SC; Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, A; Van der Bom, JG; Van Tol, A | 1 |
| Lee, R | 1 |
| Blasetto, J; Marais, AD; Palmer, M; Raal, FJ; Rader, DJ; Stein, EA; Wilpshaar, W | 1 |
| Hsu, M; Morioka, I; Muchova, L; Schröder, H; Stevenson, DK; Vitek, L; Wong, RJ; Zelenka, J | 1 |
| Betteridge, DJ; Gibson, JM; Sager, PT | 1 |
| Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Cannon, CP; Kumar, A | 1 |
| Brunetti, ND; Casavecchia, GP; De Gennaro, L; Di Biase, M; Distaso, C; Maulucci, G; Pellegrino, PL | 1 |
| Davidson, MH; Fox, KM; Gandhi, SK; Ohsfeldt, RL | 1 |
| Askew, V; Auerbach, B; Dillon, L; Hanselman, JC; Kennedy, RM; Kowala, MC; Larsen, SD; Lin, Z; Lu, GH; Miller, S; Park, WK; Robertson, A; Roth, BD; Sekerke, C; Song, Y; Steinbaugh, BA; Sun, K; Tait, BD; Trivedi, BK | 1 |
| Lee, YT; Ro, YM; Sim, KH; Sriratanasathavorn, C; Tomlinson, B; Zhu, JR | 1 |
| Chello, M; D'Ambrosio, A; Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Vetrovec, GW | 1 |
| Ai, M; Asztalos, BF; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E | 1 |
| Jukema, JW; Liem, AH; van de Woestijne, AP; Visseren, FL; Zwinderman, AH | 1 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Caputi, AP; Catania, MA; Giustini, SE; Oteri, A; Polimeni, G; Russo, A; Travaglini, R | 1 |
| Loscalzo, J; Pitt, B; Raichlen, JS; Ycas, J | 1 |
| Miller, M | 1 |
| Asmar, R; Duffield, E; Faergeman, O; Hill, L; Sosef, F; Wiklund, O; Windler, E | 1 |
| Doggrell, SA | 1 |
| Hallinen, T; Martikainen, J; Niskanen, L; Peura, P; Soini, E | 1 |
| Fox, KM; Gandhi, SK; McKenney, JM; Ohsfeldt, RL | 1 |
| Brener, SJ; Hu, T; Ivanc, TB | 1 |
| Bainbridge, G; Bills, E; Bolton, G; Bratton, LD; Caspers, NL; Dunbar, JB; Harris, MS; Hutchings, RH; Kennedy, RM; Larsen, SD; Pavlovsky, A; Pfefferkorn, JA; Sarver, RW | 1 |
| Bergheanu, SC; Bobeldijk, I; Hankemeier, T; Jukema, JW; Liem, AH; Ramaker, R; Reijmers, T; van der Greef, J; Zwinderman, AH | 1 |
| Ford, JS; Tayek, JA | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Bucci, A; Di Giacomo, S; Fraone, N; Mazza, F; Mazzarella, B; Stefanutti, C; Vivenzio, A | 1 |
| Beamer, B; Costa-Scharplatz, M; Frial, T; Gandhi, S; Ramanathan, K | 1 |
| Ballantyne, CM; Cain, VA; Raichlen, JS | 1 |
| Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M | 1 |
| Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S | 1 |
| Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Daubresse, JC; Herregods, MC; Lamotte, M; Michel, G; Vandenhoven, G; Vissers, E | 1 |
| Boccara, F; Hatem, S | 1 |
| Alonso, J; Crean, P; Danchin, N; Farah, M; Farnier, M; Lablanche, JM; Leone, A; Licour, M; Morais, J; Santini, M; Tardif, JC; Tedgui, A; Vicaut, E | 1 |
| Acimovic, J; Bernhardt, R; Kóbori, L; Kocjan, D; Köhalmy, K; Kuzman, D; Monostory, K; Pascussi, JM; Rozman, D; Szabó, P; Temesvári, M; Wilzewski, B | 1 |
| Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pavoni, M; Pocaterra, D | 1 |
| Pedersen, TR | 1 |
| Ai, M; Jones, PH; Matthan, NR; Otokozawa, S; Resteghini, NA; Schaefer, EJ; Stein, EA; van Himbergen, TM | 1 |
| Kurabayashi, M; Yamazaki, T | 1 |
| Smith, M; Sullivan, D; Wlodarczyk, J | 1 |
| Jiang, GH; Qu, HY; Wang, ZY; Xiao, YW; Zhang, M; Zhang, Y | 1 |
| Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S | 1 |
| Abel, T; Fehér, J | 1 |
| Lüscher, TF | 1 |
| Creager, MA; Donnelly, J; Ganz, P; Liao, JK; Liu, PY; Nohria, A; Rawlings, R; Selwyn, A | 1 |
| Ai, M; Asztalos, BF; Jones, PH; Otokozawa, S; Schaefer, EJ; Stein, EA; Tanaka, A; Van Himbergen, T | 1 |
| Hsia, J; Otvos, JD; Rosenson, RS | 1 |
| Fromm, MF; Keskitalo, JE; Kurkinen, KJ; Neuvonen, PJ; Niemi, M; Zolk, O | 1 |
| Hjemdahl, P; Jørgensen, L; Malmström, RE; Ostergren, J | 1 |
| Barditch-Crovo, P; Cameron, DW; Elgadi, MM; Flexner, C; Fuchs, E; la Porte, CJ; Lee, LS; Pham, PA; Piliero, PJ; Sabo, JP; van Heeswijk, R | 1 |
| Kuriyama, G; Mori, Y; Tajima, N; Tanaka, T | 1 |
| Backus, S; Lee, HB; Peart, TE; Svoboda, ML | 1 |
| Bailey, KM; Balmforth, AJ; Hall, AS; Romaine, SP | 1 |
| Andrushko, N; Andrushko, V; Börner, A; König, G; Korostylev, A; Tararov, V | 1 |
| Abate, N; Ballantyne, CM; Catapano, AL; Davidson, MH; Polis, AB; Smugar, SS; Tershakovec, AM | 1 |
| Kim, RB; Knauer, MJ; Leake, BF; Lemke, CJ; Meyer zu Schwabedissen, HE; Schwarz, UI; Tirona, RG; Urquhart, BL | 1 |
| Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Faoagali, J; Kruger, P; Welsh, AM | 1 |
| Bangit, JR; Batsell, RR; John, S; Molinella, R; Reddy, KJ; Singh, M; Varghese, S; Zaheer, MS | 1 |
| Chang, SA; Kim, DH; Kim, HK; Kim, YJ; Oh, BH; Park, YB; Sohn, DW | 1 |
| Barter, PJ; Brandrup-Wognsen, G; Nicholls, SJ; Palmer, M | 1 |
| Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K | 1 |
| Gratsianskiĭ, NA; Kuznetsova, MA; Masenko, VP; Vaulin, NA | 1 |
| Choi, D; Chung, N; Her, AY; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Manabe, I | 1 |
| Chae, JK; Choi, JY; Hong, TJ; Jeong, MH; Kim, DS; Kim, KY; Kim, YJ; Kim, YN; Oh, SK; Park, JS; Seong, IW | 1 |
| Alonso, J; Demil, N; Eha, J; Lablanche, JM; Leone, A; Licour, M; Merkely, B; Morais, J; Santini, M; Tardif, JC | 1 |
| Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P | 1 |
| Ahire, YS; Dandawate, PR; Gandhi, SP; Ghaisas, MM; Zawar, SA | 1 |
| Fujimori, S; Kaneko, K; Ogata, N; Oka, Y | 1 |
| Holford, TR; Kane, JP; Kocherla, M; Pullinger, CR; Ruaño, G; Seip, RL; Thompson, PD; Windemuth, A; Wu, AH | 1 |
| Enlund, H; Helin-Salmivaara, A; Korhonen, MJ; Martikainen, JE; Saastamoinen, LK | 1 |
| Bergheanu, SC; Dallinga-Thie, GM; Hattori, H; Karalis, IK; Liem, AH; van Tol, A; Wolterbeek, R; Wouter Jukema, J | 1 |
| Alessi, MC; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Moro, PJ; Poyet, R; Quilici, J | 1 |
| Melfi, R; Nusca, A; Patti, G; Sciascio, GD | 1 |
| Choi, MK; Choi, YL; Deng, JW; Shin, HJ; Shin, JG; Song, IS | 1 |
| Chen, YC; Hsieh, CH; Hsieh, MW; Jeng, JC; Jeng, SF; Lu, TH; Rau, CS | 1 |
| Schunn, H | 1 |
| Auteri, A; Ciabattoni, G; Ciani, F; Davì, G; Ferrante, E; Ghezzi, A; Lattanzio, S; Liani, R; Pasqui, AL; Puccetti, L; Santilli, F; Scarpini, F | 1 |
| Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A | 1 |
| Bastien, NR; Francis, GA; Genest, JJ; Goodman, SG; Langer, A; Leiter, LA; McPherson, R | 1 |
| Foley-Comer, AJ; Jordan, P; Russell-Yarde, F; Young, AM | 1 |
| Bailey, C; Capps, N; Ramachandran, S; Saraf, S; Shetty, C | 1 |
| Koh, KK; Quon, MJ; Sakuma, I | 1 |
| Ahmed, K; Ahn, Y; Cho, JG; Cho, SH; Choi, YH; Hachinohe, D; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS | 1 |
| Crane, HM; Crane, PK; Harrington, RD; Kitahata, MM; Knopp, RH; Kosel, BW; Mugavero, MJ; Saag, MS; Singh, S; Willig, JH | 1 |
| Mikhailidis, DP; Paraskevas, KI; Veith, FJ | 1 |
| Ai, M; Asztalos, BF; Himbergen, TV; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E; Thongtang, N | 1 |
| Ho, RH; Kim, RB; Leake, BF; Meyer zu Schwabedissen, HE; Mizuguchi, K; Mokrab, Y; Schwarz, UI; Suzuki, A; Tirona, RG | 1 |
| Ahmad, L; Iqbal, Z; Khan, A; Khan, MI; Nasir, F; Nazir, S; Shah, Y | 1 |
| Boutros, PC; Clendening, JW; Goard, CA; Martirosyan, A; Mather, RG; Penn, LZ; Sharom, FJ; Vinepal, B | 1 |
| Ballantyne, CM; Jones, PH; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Thakker, KM | 1 |
| Kelly, MT; Mohiuddin, SM; Setze, CM; Thakker, KM | 1 |
| Ballantyne, C; Barter, P; Borgman, M; Chapman, MJ; Erbel, R; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS | 1 |
| Iwasaki, Y; Jinnouchi, H; Matsui, K; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K | 1 |
| Ara, R; Durrington, PN; Pandor, A; Rafia, R; Rees, A; Reynolds, TM; Stevens, J; Stevenson, M; Ward, SE; Wierzbicki, AS | 1 |
| Bi, H; Chen, WA; Daugherty, A; Hong, B; Luo, Y; Wang, JA; Wang, Y; Xie, X; Zhang, S | 1 |
| Noda, K; Saku, K; Zhang, B | 2 |
| Ayaori, M; Ikewaki, K | 1 |
| Barone, E; Butterfield, DA; Mancuso, C | 1 |
| Anzivino, C; Baldelli, E; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Galli Kienle, M; Loria, P | 1 |
| Eeg-Olofsson, K; Eliasson, B; Gudbjörnsdóttir, S; Jonasson, JM; Miftaraj, M; Sundell, KA; Svensson, AM | 1 |
| Anagnostis, P; Athyros, VG; Karagiannis, A; Kita, M; Mikhailidis, DP; Panagiotidou, A; Panagiotou, A; Polyzos, SA; Selalmatzidou, D; Slavakis, A | 1 |
| Eren, MA; Koksal, M; Sabuncu, T; Turan, MN | 1 |
| Anagnostis, P; Athyros, VG; Karagiannis, A; Mikhailidis, DP | 1 |
| Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA | 1 |
| Chupka, J; Duignan, DB; El-Kattan, AF; Feng, B; Goosen, TC; Litchfield, J; Rotter, CJ; Varma, MV; Whalen, KM | 1 |
| Fujii, M; Horie, M; Ibe, K; Kawahara, C; Nakae, I; Sakai, H; Tsutamoto, T; Yamaji, M; Yamamoto, T | 1 |
| Catapano, AL; Norata, GD; Pirillo, A | 1 |
| Endo, T; Fukui, K; Himeno, H; Iwahashi, N; Iwasawa, Y; Kimura, K; Kobayashi, S; Mochida, Y; Morita, Y; Okada, K; Sawada, R; Shigemasa, T; Shimizu, M; Shimizu, T; Uchino, K; Umemura, S; Wada, A | 2 |
| Furman, A; Lopez, JR; Malmstrom, RA; Meier, JL; Schaefer, S | 1 |
| Hafner, M; Juvan, P; Monostory, K; Pascussi, JM; Rezen, T; Rozman, D | 1 |
| Bronckers, I; Hopman, MT; Rongen, GA; Smits, P; Thijssen, DH; Wever, KE; Wouters, CW | 1 |
| Itoh, T; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Charlton-Menys, V; Dissanayake, S; Durrington, PN; France, MW; Kwok, S; Soran, H; Younis, NN | 1 |
| Takagi, H; Umemoto, T | 3 |
| Bi, YA; El-Kattan, AF; Fenner, KS; Iseki, K; Kimoto, E; Lai, Y; Linder, C; Walsky, R; Whalen, KM; Xiao, Y; Yang, YS; Zhang, H | 1 |
| Ballantyne, CM; Barter, PJ; Borgman, M; Chapman, MJ; Erbel, RM; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS; Uno, K; Wolski, K | 1 |
| Akçalı, Z; Borlu, F; Namal, E; Oztekin, E; Sener, N; Ulaş, T | 1 |
| Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD | 1 |
| Schalkwijk, CG; Simsek, S; Wolffenbuttel, BH | 1 |
| DeGorter, MK; Gradhand, U; Kim, RB; Tirona, RG; Urquhart, BL | 1 |
| Schaefer, JR | 1 |
| de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
| Cao, HM; Feng, J; Li, GY; Li, J; Liu, B; Liu, M; Wang, Q | 1 |
| Loscalzo, J; Miller, E; Monyak, J; Pitt, B; Raichlen, J | 1 |
| Itoh, T; Nakamura, M; Satoh, M; Tabuchi, T | 2 |
| An, C; An, F; Dong, Z; Liu, H; Wang, Y; Wu, Y; Zhang, M; Zhang, Y | 1 |
| Choudhury, RP; Iacob, AO | 1 |
| Ahn, JM; Kang, SJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Song, HG | 1 |
| Davies, GR | 1 |
| Hitman, GA | 1 |
| Ahn, JH; Bliden, KP; Gho, EH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, S; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Tantry, US | 1 |
| Al-Azzam, S; Alnasser, Z; Alzoubi, K; Masadeh, M; Mhaidat, N | 1 |
| Filippatos, TD | 1 |
| Musella, F; Paneni, F; Perrone-Filardi, P; Savarese, G; Volpe, M | 1 |
| Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK | 3 |
| Dandri, M; Kah, J; Keller, AD; Montalbano, R; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Volz, T; Wüstenberg, A | 1 |
| Alperin, P; Gandhi, S; Hsia, J; Peskin, B; Schuetz, CA; van Herick, A | 1 |
| Elis, A; Lishner, M | 1 |
| Bruckert, E; Dallongeville, J; Rosenbaum, D; Sabouret, P | 1 |
| Heintjes, EM; Herings, RM; Meerding, WJ; Penning-van Beest, FJ; Plat, AW; Sturkenboom, MC; Webb, K | 1 |
| Chang, K; Gwon, HC; Jeon, DS; Kim, HS; Kim, MJ; Kim, SJ; Tahk, SJ | 1 |
| Iwasaki, Y; Jinnouchi, H; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K | 2 |
| Gogolashvili, NG | 1 |
| Ban, MR; Hegele, RA; Rahalkar, AR | 1 |
| Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L | 1 |
| Dimbil, M; Golomb, BA; Hoffman, KB; Kraus, C | 1 |
| Alvarez Sanz, C; Barrios, V; Brosa, M; Capel, M; Lobos, JM; Serrano, A | 1 |
| Andersen, K; Björnsdóttir, LR; Einarsdóttir, R; Gizurarson, S; Halldórsson, M | 1 |
| Bush, M; Collins, D; Generaux, G; Hussey, E; McMullen, S; Nunez, DJ; Polli, JW; Smith, G; Turner, N | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; McPeters, G; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Aeed, H; Bruck, R; Gavish, D; Sharvit, E; Shirin, H | 1 |
| DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH; Serebruany, VL | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Dormuth, CR; Ernst, P; Garg, AX; Hemmelgarn, BR; James, MT; Lafrance, JP; Levy, A; Paterson, JM; Raymond, CB; Teare, GF | 1 |
| Campbell, SM; Godman, B; Gustafsson, LL; Pichetti, S; Sermet, C | 1 |
| Balu, S; Montouchet, C; Ruff, L | 1 |
| Hu, M; Ko, GT; Lui, SS; Tomlinson, B | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; St John, J; Uno, K; Wolski, K | 1 |
| Goto, SN; Mizuno, Y; Niwa, M; Takagi, H; Umemoto, T; Yamamoto, H | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Abaci, O; Coskun, U; Kilickesmez, KO; Kocas, C; Oktay, V; Yigit, Z; Yildiz, A; Yildiz, CE | 1 |
| Biondi-Zoccai, G; Calcagno, S; Canali, E; Conti, G; Fedele, F; Lucisano, L; Mancone, M; Pennacchi, M; Sardella, G; Stio, RE | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Choi, YH; DeGorter, MK; Dresser, GK; Hegele, RA; Iwuchukwu, O; Kim, RB; Myers, K; Schwarz, UI; Suskin, N; Tirona, RG; Wei, WQ; Wilke, RA; Zou, G | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 4 |
| Aydogdu, S; Canpolat, U; Cay, S; Durmaz, T | 1 |
| de Graaf, MA; Jukema, JW | 1 |
| Reiner, Ž; Tedeschi-Reiner, E | 1 |
| Gong, HR; Huang, WY; Huang, XS; Li, XP; Zhao, SP | 1 |
| Averna, M; Bays, HE; Brudi, P; De Pellegrin, A; Farnier, M; Giezek, H; Lee, R; Lowe, RS; Majul, C; Muller-Wieland, D; Triscari, J | 1 |
| Burzynska, B; Danikiewicz, W; Gora, M; Kaminska, J; Leszczynska, A; Maciejak, A; Odolczyk, N; Plochocka, D; Siedlecka, J; Sojka, M; Swiezewska, E; Sygitowicz, G; Szkopinska, A; Tulacz, D; Warchol, I; Wysocka-Kapcinska, M | 1 |
| Bae, JH; Bae, JW; Cha, MJ; Chae, IH; Cho, MC; Kim, HS; Kwon, TG; Lee, SP; Rha, SW; Suh, JW | 1 |
| Akturk, E; Altas, Y; Atas, H; Balta, S; Can, C; Demirkol, S; Erdem, K; Korkmaz, H; Kurtoglu, E; Sincer, I; Yilmaz, M | 1 |
| Aksoy, Y; Senen, K; Sivri, N; Tekin, G; Yalta, K; Yetkin, E | 1 |
| Foody, JM; Hu, H; Neff, D; Ramey, DR; Sajjan, S; Tershakovec, AM; Tomassini, JE; Toth, PP; Tunceli, K | 1 |
| Aksakal, E; Ekinci, M; Işik, T; Kaya, A; Kaya, Y; Kurt, M; Sevimli, S; Tanboğa, IH; Topçu, S | 1 |
| Boulanger, L; Chen, SY; Kuznik, A; Lee, YC; Mardekian, J; Shah, SN | 1 |
| Andy Schuetz, C; Folse, H; Gandhi, S; Rengarajan, B; Sternhufvud, C | 1 |
| Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C | 1 |
| Mintz, GS | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Tuzcu, EM; Uno, K; Wolski, K | 1 |
| Izuhara, M; Matsuda, M; Mitsuoka, H; Shioji, K; Uegaito, T | 1 |
| An, T; Hayashi, H; Kikkawa, A; Kose, E; Matsumoto, Y | 1 |
| Campese, VM | 2 |
| Kakuda, H; Matoba, M; Nagao, S; Nakatoh, H; Takekoshi, N | 1 |
| Barroso, MV; Benjamim, CF; de Brito-Gitirana, L; Ferreira, TS; Lanzetti, M; Porto, LC; Rueff-Barroso, CR; Valença, SS | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A | 1 |
| Bauer, I; Bertolotto, M; Dallegri, F; Fabre, M; Galan, K; Lenglet, S; Mach, F; Montecucco, F; Nencioni, A; Palombo, D; Pane, B; Pelli, G; Pende, A; Python, M; Quercioli, A; Spinella, G; Vuilleumier, N | 1 |
| Hegele, RA; Joy, TR; Mahon, JL; McDonald, CG; Monjed, A; Zou, GY | 1 |
| Simonyi, G | 1 |
| Bellandi, F; Colonna, G; Di Sciascio, G; Grieco, D; Leoncini, M; Maioli, M; Patti, G; Toso, A | 1 |
| Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R | 1 |
| Abdel Hakiem, AF; Ali, HR; El-Kommos, ME; Mohamed, NA | 1 |
| Dicker, D; Elis, A; Gevrielov-Yusim, N; Goldenberg, I; Klempfner, R; Kopel, E; Matetzky, S; Pereg, D | 1 |
| Bátai-Konczos, A; Jemnitz, K; Kékesi, O; Kis, E; Szabó, K; Szabó, M; Veres, Z | 1 |
| Kuwano, T; Miura, S; Saku, K; Shimizu, T; Tanigawa, H; Uehara, Y; Zhang, B | 1 |
| Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK | 1 |
| Jinnouchi, H; Masuda, I; Matsui, K; Mori, H; Ogawa, H; Saito, Y; Sugawara, M; Sugiyama, S; Waki, M; Watada, H; Yoshiyama, M | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Cho, L; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Stegman, B; Uno, K | 1 |
| Chitose, T; Hokamaki, J; Ogawa, H; Sakamoto, K; Shimomura, H; Shiraishi, S; Sugiyama, S; Tsunoda, R; Yamashita, T; Yamashita, Y | 1 |
| Bays, HE; Colhoun, HM; Donahue, S; Du, Y; Hanotin, C; Jones, PH; Robinson, JG | 1 |
| Akinboro, O; Pomerantz, D; Williams, L | 1 |
| Joy, TR; Mahon, JL; Zou, GY | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y | 1 |
| Campos, CM; Garcia-Garcia, HM; Serruys, PW | 1 |
| Cohen Tervaert, JW; de Jong, HJ; Helle, MJ; Klungel, OH; Meyboom, RH; Niskanen, L | 1 |
| Chen, JY; Chen, PY; Duan, CY; Li, HL; Li, LW; Liu, Y; Liu, YH; Luo, JF; Tan, N; Zhou, YL | 1 |
| Duncan, BB; Polanczyk, CA; Restelatto, LM; Ribeiro, RA; Stella, SF; Vieira, JL; Ziegelmann, PK | 1 |
| Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A | 1 |
| Dostal, E; Gaspar, L; Goliasch, G; Hofbauer, SL; Huber, K; Kastl, SP; Katsaros, KM; Krychtiuk, KA; Maurer, G; Oravec, S; Pfaffenberger, S; Pongratz, T; Speidl, WS; Wojta, J; Wonnerth, A | 1 |
| Dubrovins'ka, TV; Skrypnyk, IM | 1 |
| Chan, KA; Chou, HW; Lai, CL; Lai, MS | 1 |
| Chen, M; Huang, BT | 1 |
| Nicholls, SJ; Puri, R; Shao, M; Stegman, B | 1 |
| Chen, Y; Fan, Y; Jiang, C; Liu, F; Liu, M | 1 |
| Anzalone, DA; Cain, VA; Cressman, MD; de Zeeuw, D; Heerspink, HJ; Molitoris, BA; Monyak, JT; Parving, HH; Remuzzi, G; Sowers, JR; Vidt, DG | 1 |
| Lewicki, M; Ng, I; Schneider, AG | 1 |
| Haynes, R; Wanner, C | 1 |
| Phongtuntakul, B; Tungsubutra, W | 1 |
| Bredie, SJ; Kramers, C; Lobo, CM; van der Vlugt, MJ; Willemsen, AE | 1 |
| Barter, PJ; Brewer, HB; Ford, J; Hovingh, GK; Kastelein, JJ; Rader, DJ; Round, P; Saleheen, D; van Deventer, SJ | 1 |
| Ray, KK; Vallejo-Vaz, AJ | 1 |
| Mearns, BM | 1 |
| Karpov, RS; Konko, TIu; Koshel'skaia, OA; Kravchenko, ES; Suslova, TE; Vinnitskaia, IV | 1 |
| Bao, S; Lian, QQ; Liu, H; Lv, K; Su, Y; Wang, B; Wang, H; Wang, S; Zhou, WH | 1 |
| Alves Saldanha, S; Battegay, M; Cavassini, M; Courlet, P; Decosterd, LA; Livio, F; Marzolini, C; Scherrer, A; Stoeckle, M | 1 |
| Barth, AT; Gray, HB; Morales, M; Winkler, JR | 1 |
| Farooq Ur Rehman, RM; Khokhar, SA; Masood, S | 1 |
| Dautović, E; Halilčević, D; Hatkić, A; Husejnović, MŠ; Rustemović-Čorbić, M; Smajlović, A; Softić, A; Srabović, N | 1 |
47 review(s) available for pyrroles and fluorobenzenes
| Article | Year |
|---|---|
New statins and new doses of older statins.
Topics: Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Cholesterol, LDL; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2003 |
More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Pyrimidines; Pyrroles; Racial Groups; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2004 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
Rosuvastatin-induced arrest in progression of renal disease.
Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Anxioselective anxiolytics: can less be more?
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepinones; Carbolines; Clinical Trials as Topic; Fluorobenzenes; GABA-A Receptor Agonists; Humans; Indoles; Pyrroles; Quinolones; Triazoles | 2004 |
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis a
Topics: Animals; Atorvastatin; Chromatography, High Pressure Liquid; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pharmaceutical Preparations; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
The clinical relevance of low-density-lipoproteins size modulation by statins.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Particle Size; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
How safe is aggressive statin therapy?
Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
Topics: Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medical Records Systems, Computerized; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
[Pleiotropic effects of statins].
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2008 |
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Fluorobenzenes; Gene Frequency; Haplotypes; HeLa Cells; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Highly stereoselective hydrogenations--as key-steps in the total synthesis of statins.
Topics: Atorvastatin; Fluorobenzenes; Heptanoic Acids; Hydrogenation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stereoisomerism; Sulfonamides | 2010 |
Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers, Pharmacological; Confidence Intervals; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Kidney Diseases; Multivariate Analysis; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2010 |
Differential metabolic effects of distinct statins.
Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Optimal statin type and dosage for vascular patients.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Tolerance; Endovascular Procedures; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrimidines; Pyrroles; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Vascular Diseases; Vascular Surgical Procedures | 2011 |
A meta-analysis of randomized head-to-head trials of atorvastatin versus rosuvastatin for reductions in C-reactive protein.
Topics: Atorvastatin; C-Reactive Protein; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2012 |
Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials.
Topics: Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Stroke Volume; Sulfonamides | 2012 |
[HDL level or HDL function as the primary target in preventive cardiology].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Membrane Transport Proteins; Myocardial Infarction; Niacin; Pyrimidines; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reference Values; Rosuvastatin Calcium; Scavenger Receptors, Class B; Sulfonamides; Survival Rate; Up-Regulation | 2012 |
Effects of rosuvastatin and atorvastatin on renal function: meta-analysis.
Topics: Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Proteinuria; PubMed; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2012 |
Targeting HDL-cholesterol to reduce residual cardiovascular risk.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis.
Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Databases, Factual; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2012 |
Non-every day statin administration--a literature review.
Topics: Atorvastatin; Cardiovascular Diseases; Drug Administration Schedule; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
[Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine].
Topics: Atorvastatin; Biological Availability; Cardiovascular Diseases; Dose-Response Relationship, Drug; Evidence-Based Medicine; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Therapeutic Equivalency | 2012 |
Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease.
Topics: Atherosclerosis; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2013 |
Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER.
Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
Topics: Acute Kidney Injury; Adult; Aged; Atorvastatin; British Columbia; Cohort Studies; Confidence Intervals; Databases, Factual; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Safety; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United Kingdom; United States | 2013 |
Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials.
Topics: Atorvastatin; Biomarkers; Chi-Square Distribution; Down-Regulation; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Particle Size; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles.
Topics: Apolipoproteins; Atorvastatin; Coronary Artery Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.
Topics: Acute Kidney Injury; Adult; Atorvastatin; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Artery Bypass; Creatinine; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Replacement Therapy; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
[Choosing wisely when prescribing statins].
Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quality of Health Care; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
140 trial(s) available for pyrroles and fluorobenzenes
| Article | Year |
|---|---|
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Reference Values; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2001 |
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Canada; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; United States | 2002 |
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2002 |
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Linear Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2003 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2003 |
Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Analysis of Variance; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Least-Squares Analysis; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Treatment Outcome | 2003 |
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2003 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study.
Topics: Apolipoproteins B; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2004 |
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Logistic Models; Male; Middle Aged; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2004 |
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2004 |
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2004 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
Topics: Adolescent; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2005 |
The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Program Evaluation; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2005 |
Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients.
Topics: Aged; Albuminuria; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2006 |
LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2005 |
Achieving lipid goals in real life: the Dutch DISCOVERY study.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial.
Topics: Adult; Aged; Atorvastatin; Black or African American; C-Reactive Protein; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2006 |
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2006 |
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study).
Topics: Atorvastatin; Blood Proteins; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2006 |
Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Europe; Female; Fluorobenzenes; Guidelines as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Male; Meta-Analysis as Topic; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Social Change; Sulfonamides | 2006 |
Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare?
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2006 |
Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
Topics: Adult; Atorvastatin; Cholesterol, LDL; Delayed-Action Preparations; Drug Combinations; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Niacin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, HDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2007 |
Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
[Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/l in high cardiovascular risk patients (ARIANE study)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Creatinine; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Managed Care Programs; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoprotein A-I; Asian People; Atorvastatin; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2007 |
Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Topics: Adult; Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Models, Economic; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
[The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia in Chinese: a randomized, double-blind, multi-center clinical trial].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Asian People; Atorvastatin; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2007 |
Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
Topics: Adult; Aged; Aged, 80 and over; Aryldialkylphosphatase; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Double-Blind Method; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Atorvastatin; Child; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2008 |
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; England; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North Carolina; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg.
Topics: Aged; Atorvastatin; C-Reactive Protein; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Regional Blood Flow; Rosuvastatin Calcium; Sulfonamides; Vasodilation | 2007 |
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
Topics: Anticholesteremic Agents; Asia; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2007 |
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels.
Topics: Aged; Atorvastatin; Cell Count; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
Topics: Aged; Atorvastatin; Canada; Cholesterol, LDL; Coronary Disease; European Union; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2008 |
Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins.
Topics: Atorvastatin; Chromatography, Liquid; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Mass Spectrometry; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2008 |
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvas
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia.
Topics: Atorvastatin; Belgium; Cholesterol, LDL; Female; Fluorobenzenes; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Logistic Models; Male; Markov Chains; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Double-Blind Method; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers.
Topics: Absorption; Adult; Aged; Atorvastatin; Biomarkers; Cholesterol; Diabetes Complications; Female; Fluorobenzenes; Glycated Serum Albumin; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Phytosterols; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serum Albumin; Sterols; Sulfonamides | 2009 |
Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia.
Topics: Adiponectin; Adult; Aged; Atorvastatin; Biomarkers; Brachial Artery; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation Mediators; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2009 |
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.
Topics: Aged; Atherosclerosis; Atorvastatin; Brachial Artery; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Regional Blood Flow; rho-Associated Kinases; Rosuvastatin Calcium; Sulfonamides; White People | 2009 |
Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Placebos; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides; White People | 2009 |
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
Topics: Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cross-Over Studies; Drug Resistance, Multiple; Female; Finland; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Reference Values; Rosuvastatin Calcium; Sulfonamides; White People | 2009 |
Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2009 |
Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Atorvastatin; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyridines; Pyrimidines; Pyrones; Pyrroles; Ritonavir; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2009 |
Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.
Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Persistent regional diastolic dysfunction after myocardial ischemia and the effect of statin treatment: assessment with two-dimensional radial strain rate.
Topics: Angina Pectoris, Variant; Atorvastatin; Diastole; Exercise Test; Female; Fluorobenzenes; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pyrimidines; Pyrroles; Reference Standards; Rosuvastatin Calcium; Sulfonamides; Ultrasonography; Ventricular Dysfunction, Left | 2010 |
[Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Data Interpretation, Statistical; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Lipids; Lipoproteins; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Tumor Necrosis Factor-alpha | 2010 |
Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, LDL; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Glucose; Glycated Hemoglobin; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.
Topics: Atorvastatin; Blood Glucose; Cholesterol, LDL; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Insulin; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome | 2010 |
Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Uric Acid | 2010 |
Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Carrier Proteins; Dose-Response Relationship, Drug; Enzymes; Female; Fluorobenzenes; Heptanoic Acids; Humans; Inflammation; Lipid Metabolism; Lipoproteins; Male; Maximum Tolerated Dose; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2010 |
Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronar
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stents; Sulfonamides; Ticlopidine | 2010 |
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia.
Topics: 3' Untranslated Regions; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Oxidative Stress; Platelet Activation; Polymorphism, Genetic; Prospective Studies; Prostaglandins A; Pyrimidines; Pyrroles; Regression Analysis; Rosuvastatin Calcium; Sulfonamides; Thromboxane B2 | 2011 |
Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
Topics: Adolescent; Adult; Aged; Area Under Curve; Atorvastatin; Cross-Over Studies; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Thiophenes; Young Adult | 2011 |
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
Topics: Adiponectin; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus; Female; Fluorobenzenes; Glucose; Glycated Serum Albumin; Glycation End Products, Advanced; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serum Albumin; Sulfonamides; Triglycerides | 2011 |
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2011 |
Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2011 |
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN).
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography | 2011 |
Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Echocardiography; Exercise; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Smoking; Sulfonamides; Ubiquinone | 2011 |
Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
Topics: Aged; Analysis of Variance; Atorvastatin; Biomarkers; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Patient Selection; Prospective Studies; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study.
Topics: Adipokines; Aged; Atorvastatin; Blood Glucose; Cholesterol; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2011 |
The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients.
Topics: Adolescent; Adult; Aged; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Oxidative Stress; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Young Adult | 2011 |
Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy.
Topics: Aged; Atorvastatin; Cardiomyopathy, Dilated; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pyrimidines; Pyrroles; Radionuclide Imaging; Rosuvastatin Calcium; Stroke Volume; Sulfonamides; Sympathetic Nervous System; Time Factors | 2011 |
Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.-.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Short-term statin treatment does not prevent ischemia and reperfusion-induced endothelial dysfunction in humans.
Topics: 5'-Nucleotidase; Adolescent; Adult; Atorvastatin; Blood Pressure; Brachial Artery; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Female; Fluorobenzenes; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Time Factors; Vasodilation; Young Adult | 2012 |
Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: effect of statins on let-7i and Toll-like receptor 4 signal.
Topics: Aged; Atorvastatin; Cell Line; Coronary Artery Disease; Down-Regulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Toll-Like Receptor 4 | 2012 |
Effect of two intensive statin regimens on progression of coronary disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2011 |
[Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial].
Topics: Angina, Unstable; Atorvastatin; Azetidines; C-Reactive Protein; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Single-Blind Method; Sulfonamides; Treatment Outcome | 2011 |
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Topics: Aged; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study.
Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Fasting; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2012 |
Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects.
Topics: Adult; Animals; Area Under Curve; Atorvastatin; Cross-Over Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver-Specific Organic Anion Transporter 1; Male; Mice; Mice, Knockout; Middle Aged; Organic Anion Transporters, Sodium-Independent; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Young Adult | 2012 |
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis.
Topics: Atherosclerosis; Atorvastatin; C-Reactive Protein; Endothelium, Vascular; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Phosphorylation; Protein Subunits; Pyrimidines; Pyrroles; rho-Associated Kinases; Rosuvastatin Calcium; Sulfonamides; Vasodilation | 2011 |
[Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial].
Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
Topics: Acute Coronary Syndrome; Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Survival Rate; Treatment Outcome; United States; Young Adult | 2012 |
MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression.
Topics: Aged; Atorvastatin; Cell Count; Cell Movement; Cells, Cultured; Coronary Artery Disease; Endothelial Cells; Female; Fluorobenzenes; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Longevity; Male; MicroRNAs; Oxidative Stress; Pyrimidines; Pyrroles; RNA, Messenger; Rosuvastatin Calcium; Sirtuin 1; Sulfonamides; Transfection | 2012 |
Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
Topics: Atorvastatin; Coronary Angiography; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Republic of Korea; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2012 |
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Substitution; Drug Therapy, Combination; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2012 |
Combination treatment of rosuvastatin or atorvastatin, with regular exercise improves arterial wall stiffness in patients with coronary artery disease.
Topics: Atorvastatin; Coronary Artery Disease; Exercise; Fluorobenzenes; Heptanoic Acids; Humans; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Vascular Stiffness | 2012 |
Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Phytosterols; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Demography; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Madin Darby Canine Kidney Cells; Male; Mesylates; Middle Aged; Oxadiazoles; Piperidines; Pyrimidines; Pyrroles; Reference Standards; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Troleandomycin; Young Adult | 2013 |
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Combinations; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides | 2013 |
Factors underlying regression of coronary atheroma with potent statin therapy.
Topics: Analysis of Variance; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Endosonography; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
Topics: Aged; Angina, Stable; Atorvastatin; Elective Surgical Procedures; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Necrosis; Percutaneous Coronary Intervention; Postoperative Complications; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cholesterol; Cohort Studies; Cytochrome P-450 CYP3A; Databases, Factual; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linear Models; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasm Proteins; Organic Anion Transporters; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2013 |
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2013 |
NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin.
Topics: Aged; Atorvastatin; Carrier Proteins; Case-Control Studies; Cell Line, Tumor; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammasomes; Interleukin-18; Interleukin-1beta; Lipids; Male; Middle Aged; NLR Family, Pyrin Domain-Containing 3 Protein; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Apolipoprotein A-V; Apolipoproteins A; Atorvastatin; Bezafibrate; Cholesterol, HDL; Drug Synergism; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2013 |
C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
Topics: Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prognosis; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2014 |
Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease.
Topics: Arginine; Atorvastatin; Biomarkers; Coronary Angiography; Coronary Stenosis; Down-Regulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome; Turkey | 2014 |
Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
Topics: Atorvastatin; Contrast Media; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Fluorobenzenes; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Turkey | 2013 |
Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy--the PEARL randomized cross-over study.
Topics: Atorvastatin; Blood Platelets; Cholesterol, LDL; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP3A; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Research Design; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional | 2014 |
Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Drug Substitution; Dyslipidemias; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Societies, Medical; Sulfonamides; Time Factors; Treatment Outcome | 2014 |
Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.
Topics: Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Male; Middle Aged; Pyrimidines; Pyrroles; Quinolines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid | 2014 |
N-of-1 (single-patient) trials for statin-related myalgia.
Topics: Aged; Aged, 80 and over; Atorvastatin; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Sulfonamides | 2014 |
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2014 |
[Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis].
Topics: Atorvastatin; Bilirubin; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipids; Liver; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Transaminases; Triglycerides; Ursodeoxycholic Acid | 2014 |
Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabete
Topics: Asian People; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography | 2014 |
Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction - a pilot study.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Echocardiography; Fatty Acids; Female; Fluorobenzenes; Heart; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iodobenzenes; Male; Middle Aged; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Pilot Projects; Prospective Studies; Pyrimidines; Pyrroles; Radionuclide Imaging; Rosuvastatin Calcium; Sulfonamides; Thallium; Tomography, Emission-Computed, Single-Photon; Ubiquinone | 2014 |
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention.
Topics: Aged; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome | 2014 |
[Efficacy and safety comparison of different statins in elderly patients].
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
Topics: Adult; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Creatinine; Diabetes Complications; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Fluorobenzenes; Heptanoic Acids; Humans; Kidney; Lipids; North America; Proteinuria; Pyrimidines; Pyrroles; Rosuvastatin Calcium; South America; Sulfonamides | 2015 |
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Denmark; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Young Adult | 2015 |
[Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
Topics: Adipokines; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Glucose; Carbohydrate Metabolism; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
Comparison of efficiency between Rosuvastatin and Atorvastatin in reducing low-density lipoprotein (LDL-C) in patients with diabetes mellitus.
Topics: Atorvastatin; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2022 |
147 other study(ies) available for pyrroles and fluorobenzenes
| Article | Year |
|---|---|
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
Topics: Binding Sites; Escherichia coli; Folic Acid Antagonists; Models, Molecular; Protein Conformation; Structure-Activity Relationship | 1985 |
[60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2001 |
Effects of fibrates on metabolism of statins in human hepatocytes.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C8; Fenofibrate; Fluorobenzenes; Gemfibrozil; Glucuronosyltransferase; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; In Vitro Techniques; Microsomes, Liver; Oxidation-Reduction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2002 |
Introduction: rosuvastatin--an efficacy assessment based on pooled trial data.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Meta-Analysis as Topic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2003 |
Is there a "best" statin drug?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Development of an efficient, scalable, aldolase-catalyzed process for enantioselective synthesis of statin intermediates.
Topics: Amino Acid Sequence; Atorvastatin; Catalysis; Fluorobenzenes; Fructose-Bisphosphate Aldolase; Heptanoic Acids; Molecular Sequence Data; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stereoisomerism; Sulfonamides | 2004 |
Update on statins.
Topics: Atorvastatin; Coronary Disease; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
Topics: Atorvastatin; Coronary Disease; Fluorobenzenes; Goals; Heptanoic Acids; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect?
Topics: Acute Disease; Aged; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatitis; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides | 2004 |
Assessment of the efficacy of different statins in murine collagen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Atorvastatin; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lymph Nodes; Male; Mice; Mice, Inbred DBA; Nuclear Proteins; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Trans-Activators; Treatment Outcome | 2004 |
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Not all statins interfere with clopidogrel during antiplatelet therapy.
Topics: Adult; Atorvastatin; Chromatography, High Pressure Liquid; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2005 |
Binding thermodynamics of statins to HMG-CoA reductase.
Topics: Atorvastatin; Binding Sites; Calorimetry; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Protein Binding; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Thermodynamics | 2005 |
Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
New light on statin side effects. What recent research on the cholesterol drugs means to you.
Topics: Atorvastatin; Biomedical Research; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Decreasing LDL cholesterol and medication cost with every-other-day statin therapy.
Topics: Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2005 |
Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microsomes, Liver; Molecular Structure; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Swine; Transfection | 2006 |
[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Placebos; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2006 |
Atorvastatin for stroke prevention.
Topics: Atorvastatin; Cerebral Hemorrhage, Traumatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Muscular Diseases; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Time Factors | 2006 |
Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2006 |
Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Audit; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2007 |
Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes.
Topics: Antifungal Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Synergism; Fluorobenzenes; Fungi; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Microbial Sensitivity Tests; Penicillium chrysogenum; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spores, Fungal; Sulfonamides | 2007 |
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
Topics: Administration, Oral; Adult; Area Under Curve; Atorvastatin; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Polymorphism, Genetic; Prospective Studies; Pyrimidines; Pyrroles; Reference Values; Rosuvastatin Calcium; Sulfonamides; White People | 2007 |
Statin wars: emphasis on potency vs event reduction and safety?
Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Topics: Animals; Cricetinae; Dose-Response Relationship, Drug; Drug Design; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver; Models, Molecular; Molecular Structure; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Structure-Activity Relationship; Sulfonamides | 2007 |
Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion.
Topics: Atorvastatin; C-Reactive Protein; CCAAT-Enhancer-Binding Proteins; Cells, Cultured; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoassay; Interleukin-6; Mevalonic Acid; Pyrimidines; Pyrroles; RNA, Messenger; Rosuvastatin Calcium; STAT3 Transcription Factor; Sulfonamides; Transcription Factors | 2007 |
Ask the doctor. Are Lipitor and Crestor equally good for me?
Topics: Atorvastatin; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Insurance, Pharmaceutical Services; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Therapeutic Equivalency | 2007 |
Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection.
Topics: Animals; Antioxidants; Atorvastatin; Bilirubin; Carbon Monoxide; Carboxyhemoglobin; Fluorobenzenes; Heme Oxygenase (Decyclizing); Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Liver Function Tests; Mice; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Topics: Animals; Atorvastatin; Combinatorial Chemistry Techniques; Disease Models, Animal; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Molecular Structure; Muscle Cells; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Length of Stay; Male; Middle Aged; Multivariate Analysis; Pravastatin; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Determinants of CRP level in statin-treated patients.
Topics: Atorvastatin; Blood Pressure; C-Reactive Protein; Enzyme Inhibitors; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Pilot Projects; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; Sulfonamides | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
Gynecomastia possibly induced by rosuvastatin.
Topics: Atorvastatin; Fluorobenzenes; Gynecomastia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Probability; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Steroids; Sulfonamides | 2008 |
Lipid levels after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Triglycerides | 2008 |
Lipid levels in the post-acute coronary syndrome setting: destabilizing another myth?
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Prognosis; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2008 |
Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
Topics: Atorvastatin; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Finland; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Expectancy; Male; Markov Chains; Middle Aged; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Topics: Animals; Binding Sites; Calorimetry; Cells, Cultured; Crystallography, X-Ray; Drug Design; Fluorobenzenes; Hepatocytes; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Mice; Microsomes, Liver; Models, Molecular; Molecular Structure; Muscle Cells; Pyrimidines; Pyrroles; Rats; Rosuvastatin Calcium; Structure-Activity Relationship; Sulfonamides; Thermodynamics | 2008 |
Lipophilicity and cardiovascular outcome in patients with CHF.
Topics: Aged; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; British Columbia; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2008 |
Impact of adherence to statins on chronic heart failure in primary prevention.
Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2008 |
Statin, the black box.
Topics: Acute Coronary Syndrome; Atorvastatin; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent.
Topics: Anticholesteremic Agents; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cholesterol; Cytochrome P-450 CYP3A; Drug Interactions; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2009 |
Intensive lipid-lowering therapy for patients with aortic stenosis.
Topics: Aortic Valve Stenosis; Atorvastatin; Clinical Trials as Topic; Disease Progression; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
[Statin therapy and muscle disorders].
Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
[Comment from the cardiologic viewpoint].
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels.
Topics: Apolipoprotein B-48; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intestinal Mucosa; Lipoproteins; Liver; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2009 |
Occurrence and fate of rosuvastatin, rosuvastatin lactone, and atorvastatin in Canadian sewage and surface water samples.
Topics: Atorvastatin; Chromatography, Liquid; Fluorobenzenes; Heptanoic Acids; Lactones; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sewage; Solid Phase Extraction; Sulfonamides; Tandem Mass Spectrometry; Water Pollutants, Chemical | 2009 |
Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
Topics: Atorvastatin; Cell Survival; Cells, Cultured; Fluorobenzenes; Gene Expression Profiling; HeLa Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Immunohistochemistry; Multidrug Resistance-Associated Proteins; Muscle, Skeletal; Myoblasts; Organic Anion Transporters; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides | 2010 |
Antimicrobial action of atorvastatin and rosuvastatin.
Topics: Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Bacteria; Dose-Response Relationship, Drug; Ethanol; Fluorobenzenes; Heptanoic Acids; Humans; Methanol; Microbial Sensitivity Tests; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2009 |
Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use.
Topics: Allylamine; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Monitoring; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pulse Therapy, Drug; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2009 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models.
Topics: Alkaline Phosphatase; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atorvastatin; Edema; Fluorobenzenes; Granuloma; Heptanoic Acids; L-Lactate Dehydrogenase; Liver; Mice; Pain; Pain Measurement; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Rosuvastatin Calcium; Stomach Ulcer; Sulfonamides | 2010 |
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
Topics: Acetyl-CoA Carboxylase; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Sectional Studies; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Impact of restricted reimbursement on the use of statins in Finland: a register-based study.
Topics: Atorvastatin; Female; Finland; Fluorobenzenes; Health Policy; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; National Health Programs; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Registries; Reimbursement Mechanisms; Rosuvastatin Calcium; Sulfonamides | 2010 |
Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors.
Topics: Animals; Atorvastatin; Estrone; Fluorobenzenes; Genetic Variation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Oocytes; Organic Anion Transporters; Organic Anion Transporters, Sodium-Dependent; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Symporters; Taurocholic Acid; Xenopus laevis | 2011 |
Involvement of the p38 pathway in the differential induction of heme oxygenase-1 by statins in Neuro-2A cells exposed to lipopolysaccharide.
Topics: Animals; Atorvastatin; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cerebral Cortex; Dose-Response Relationship, Drug; Enzyme Induction; Fluorobenzenes; Heme Oxygenase-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Iron Chelating Agents; Lipopolysaccharides; Mice; Neurons; p38 Mitogen-Activated Protein Kinases; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; Structure-Activity Relationship; Sulfonamides | 2011 |
[On the current debate on lowering LDL cholesterol with ezetimibe].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Financing, Personal; Fluorobenzenes; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Myocardial Infarction; National Health Programs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2010 |
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides | 2011 |
Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS).
Topics: Aged; Atorvastatin; Canada; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Prevalence; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2010 |
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cohort Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Serum; Sulfonamides | 2011 |
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.
Topics: Amino Acid Sequence; Amino Acid Substitution; Atorvastatin; Fluorobenzenes; Gene Expression; HeLa Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Molecular Sequence Data; Mutagenesis, Site-Directed; Organic Anion Transporters, Sodium-Independent; Polymorphism, Genetic; Protein Conformation; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sincalide; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Substrate Specificity; Sulfonamides | 2011 |
Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: method development, validation and optimization of various experimental parameters.
Topics: Atorvastatin; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Stability; Fluorobenzenes; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Linear Models; Methanol; Pyrimidines; Pyrroles; Reproducibility of Results; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides; Water | 2011 |
Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Ovarian Neoplasms; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Tumor Cells, Cultured | 2010 |
Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
Topics: Atorvastatin; Bayes Theorem; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Costs; Drug Prescriptions; Drugs, Generic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Markov Chains; Medication Adherence; Models, Economic; Pyrimidines; Pyrroles; Quality Indicators, Health Care; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.
Topics: Angiotensin II; Animal Feed; Animals; Anti-Inflammatory Agents; Aorta; Aortic Aneurysm, Abdominal; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pressure; Fluorobenzenes; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2011 |
Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?
Topics: Analysis of Variance; Atorvastatin; Biomarkers; Cholesterol, LDL; Evidence-Based Medicine; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Patient Selection; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders.
Topics: Alzheimer Disease; Animals; Atorvastatin; Cholesterol; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Neurodegenerative Diseases; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Female; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxylation; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes Register.
Topics: Adolescent; Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Registries; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Sweden; Treatment Outcome | 2011 |
Impact of statins on glucose metabolism--a matter of debate.
Topics: Atorvastatin; Fluorobenzenes; Glucose; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2011 |
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.
Topics: Atorvastatin; Caco-2 Cells; Cell Line; Chromatography, Liquid; Estrone; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Intestinal Absorption; Organic Anion Transporters; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Tandem Mass Spectrometry | 2011 |
Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Clinical Trials as Topic; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United States | 2011 |
The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action.
Topics: Atorvastatin; Cells, Cultured; Cholesterol; Constitutive Androstane Receptor; Energy Metabolism; Fluorobenzenes; Gene Expression Regulation; Gene Regulatory Networks; Hepatocytes; Heptanoic Acids; Homeostasis; Humans; Membrane Transport Proteins; Metabolic Networks and Pathways; Oligonucleotide Array Sequence Analysis; Pregnane X Receptor; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Reproducibility of Results; Rosuvastatin Calcium; Sulfonamides; Transcriptome | 2011 |
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reference Values; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2011 |
Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes.
Topics: Anti-Anxiety Agents; Anticholesteremic Agents; Atorvastatin; Bile; Biological Transport; Cell Survival; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Humans; Isoenzymes; Midazolam; Models, Biological; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Triazoles | 2012 |
[Symptomatic coronary heart disease. Impressive plaque reduction with high dose statins].
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Survival Rate | 2011 |
Reversible dysphasia and statins.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Anxiety; Aphasia; Atorvastatin; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Indapamide; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
Statins and glycaemic control--a cause for concern?
Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin.
Topics: Anti-Bacterial Agents; Atorvastatin; Drug Resistance, Multiple, Bacterial; Fluorobenzenes; Gram-Negative Bacteria; Gram-Positive Bacteria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microbial Sensitivity Tests; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cholesterol; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Suppressor Protein p53 | 2012 |
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Computer Simulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides | 2012 |
Discontinuation of statin therapy due to muscular side effects: a survey in real life.
Topics: Adult; Aged; Atorvastatin; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Motor Activity; Muscle Cramp; Muscle Weakness; Muscle, Skeletal; Musculoskeletal Diseases; Pain; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2013 |
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Netherlands; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Chi-Square Distribution; Drug Utilization; Drug Utilization Review; Evidence-Based Medicine; Female; Fluorobenzenes; Guideline Adherence; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Registries; Republic of Korea; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2012 |
Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Drugs, Generic; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Therapeutic Equivalency; Treatment Outcome; Triglycerides | 2013 |
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Topics: Atorvastatin; Databases, Factual; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tendons; United States; United States Food and Drug Administration | 2012 |
Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Primary Prevention; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Spain; Sulfonamides | 2012 |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Iceland; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reimbursement Mechanisms; Rosuvastatin Calcium; Simvastatin; Social Security; Sulfonamides; Treatment Outcome | 2012 |
Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Fluorobenzenes; Hepatic Stellate Cells; Heptanoic Acids; Hypertension, Portal; In Vitro Techniques; Incidence; Injections; Liver Cirrhosis; Liver Cirrhosis, Experimental; Male; Oxidative Stress; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Thioacetamide | 2013 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus; Drug Prescriptions; Drugs, Generic; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; France; General Practitioners; Heart Diseases; Heptanoic Acids; Humans; Indoles; Lipid Metabolism Disorders; Male; Middle Aged; Models, Statistical; Practice Patterns, Physicians'; Pravastatin; Prescription Drugs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States | 2013 |
Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies.
Topics: Aged; Anticholesteremic Agents; Asian People; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Hong Kong; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; White People | 2013 |
Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Dose-Response Relationship, Drug; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Odds Ratio; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2013 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Comparison of rosuvastatin versus atorvastatin for preventing postoperative atrial fibrillation.
Topics: Atorvastatin; Atrial Fibrillation; Comorbidity; Coronary Artery Bypass; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Premedication; Prevalence; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Turkey | 2013 |
High dose statins should be used in all patients undergoing percutaneous coronary intervention.
Topics: Elective Surgical Procedures; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Pyrimidines; Pyrroles; Sulfonamides | 2013 |
High coronary plaque load: a heavy burden.
Topics: Atorvastatin; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Prevalence and types of persistent dyslipidemia in patients treated with statins.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Croatia; Cross-Sectional Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2013 |
The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.
Topics: Atorvastatin; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fungal Proteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoenzymes; Mevalonic Acid; Organisms, Genetically Modified; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Saccharomyces cerevisiae; Simvastatin; Sterols; Sulfonamides; Terpenes | 2013 |
Statins decrease mean platelet volume irrespective of cholesterol lowering effect.
Topics: Adult; Atorvastatin; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Mean Platelet Volume; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2013 |
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol, LDL; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Managed Care Programs; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United States | 2013 |
Moving branded statins to lowest copay tier improves patient adherence.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cross-Sectional Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medicare Part D; Middle Aged; Patient Compliance; Prescription Drugs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; United States | 2014 |
Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Computer Simulation; Drug Substitution; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Middle Aged; Models, Biological; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
Beyond greyscale IVUS assessment of progression/regression: it should be simple, but it's not.
Topics: Atorvastatin; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Statins combined with exercise are associated with the increased renal function mediated by high-molecular-weight adiponectin in coronary artery disease patients.
Topics: Adiponectin; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Combined Modality Therapy; Coronary Artery Disease; Exercise Therapy; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Molecular Weight; Multivariate Analysis; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperuricemia; Kidney; Male; Middle Aged; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Uric Acid | 2014 |
Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Inhalation Exposure; Lung; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Smoking; Sulfonamides | 2014 |
Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Stenosis; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Neutrophil Activation; Neutrophils; NF-kappa B; Osteopontin; Osteoprotegerin; Pyrimidines; Pyrroles; RANK Ligand; Risk Factors; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Summaries for patients. Treatment trials to determine whether statins are the cause of a patient's discomfort.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Sulfonamides | 2014 |
[Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Databases, Factual; Drug Prescriptions; Drug Therapy, Combination; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Health; Male; Middle Aged; Patient Compliance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2014 |
Impact of high-dose statin pre-treatment and contrast-induced acute kidney injury on follow-up events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Atorvastatin; Contrast Media; Disease-Free Survival; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Micellar electrokinetic chromatographic determination of rosuvastatin in rabbit plasma and evaluation of its pharmacokinetics and interaction with niacin.
Topics: Animals; Atorvastatin; Chromatography, Micellar Electrokinetic Capillary; Drug Interactions; Fluorobenzenes; Heptanoic Acids; Hydrogen-Ion Concentration; Limit of Detection; Linear Models; Male; Niacin; Pyrimidines; Pyrroles; Rabbits; Reproducibility of Results; Rosuvastatin Calcium; Sodium Dodecyl Sulfate; Sulfonamides | 2014 |
Temporal trends in the use of high-dose potent statins following acute coronary syndrome in Israel.
Topics: Analysis of Variance; Angina, Unstable; Atorvastatin; Cohort Studies; Drug Prescriptions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Israel; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Patient Discharge; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes.
Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Bilirubin; Biological Transport; Cell Culture Techniques; Cells, Cultured; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Pravastatin; Pyrimidines; Pyrroles; Rats; Rosuvastatin Calcium; Sulfonamides | 2014 |
Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; Biological Transport; Cell Line; Cholesterol Esters; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, VLDL; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2014 |
Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
Topics: Aged; Atorvastatin; C-Reactive Protein; Comorbidity; Coronary Artery Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sex Factors; Sulfonamides; Ultrasonography, Interventional | 2014 |
N-of-1 (single-patient) trials for statin-related myalgia.
Topics: Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Sulfonamides | 2014 |
N-of-1 (single-patient) trials for statin-related myalgia.
Topics: Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Sulfonamides | 2014 |
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Women are from SATURN and men are from an ASTEROID: deciphering the REVERSAL of coronary atheroma.
Topics: Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Sulfonamides; Ultrasonography | 2014 |
Giant cell arteritis and polymyalgia rheumatica after reexposure to a statin: a case report.
Topics: Aged; Atorvastatin; Female; Fluorobenzenes; Giant Cell Arteritis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Polymyalgia Rheumatica; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
Topics: Aged; Aged, 80 and over; Atorvastatin; Brazil; Cardiovascular Diseases; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Economic; National Health Programs; Primary Prevention; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2015 |
Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease.
Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Female; Fluorobenzenes; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Heptanoic Acids; Humans; Inflammation; Interleukin-10; Lipids; Lipoproteins, HDL; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Monocytes; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
[Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis].
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2014 |
Effects of atorvastatin and rosuvastatin on renal function in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Atorvastatin; China; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Taiwan | 2015 |
Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120.
Topics: Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2015 |
Response to Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120.
Topics: Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2015 |
Statins and the kidney: friend or foe?
Topics: Diabetes Complications; Diabetic Nephropathies; Fluorobenzenes; Heptanoic Acids; Humans; Kidney; Pyrimidines; Pyrroles; Sulfonamides | 2015 |
Switching from high-efficacy lipid-lowering therapies [atorvastatin or rosuvastatin] to simvastatin and the results on low-density lipoprotein cholesterol level.
Topics: Atorvastatin; Drugs, Essential; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Thailand | 2015 |
Chronic kidney disease: Statins in chronic kidney disease: time to move on?
Topics: Diabetes Complications; Diabetic Nephropathies; Fluorobenzenes; Heptanoic Acids; Humans; Kidney; Pyrimidines; Pyrroles; Sulfonamides | 2015 |
Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Thailand; Treatment Outcome | 2015 |
The evolving role of CETP inhibition: beyond HDL cholesterol.
Topics: Cholesterol Ester Transfer Proteins; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Quinolines; Sulfonamides | 2015 |
Dyslipidaemia: Promising results for TA-8995 in TULIP.
Topics: Cholesterol Ester Transfer Proteins; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Quinolines; Sulfonamides | 2015 |
Contribution of the α5 GABAA receptor to the discriminative stimulus effects of propofol in rat.
Topics: Animals; Carbolines; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Fluorobenzenes; GABA-A Receptor Agonists; GABA-A Receptor Antagonists; Imidazoles; Indoles; Male; Propofol; Pyridazines; Pyrroles; Random Allocation; Rats, Sprague-Dawley; Receptors, GABA-A; Triazoles | 2018 |
Real-life management of drug-drug interactions between antiretrovirals and statins.
Topics: Cohort Studies; Drug Interactions; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pharmaceutical Preparations; Pyrroles | 2020 |
Photoredox Catalysis Mediated by Tungsten(0) Arylisocyanides in 1,2-Difluorobenzene.
Topics: Catalysis; Cyclization; Fluorobenzenes; Pyrroles; Tungsten | 2022 |
Some pleiotropic effects of statins on hepatocellular carcinoma cells: Comparative study on atorvastatin, rosuvastatin and simvastatin.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Fluorobenzenes; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Pyrimidines; Pyrroles; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2023 |